VEGF (Vascular endothelial growth factor-121) Price
BACKGROUND: Vascular endothelial growth factor (VEGF) is a potent angiogenic factor, and its expression is induced by hypoxia. VEGF also
possesses a non-angiogenic role important for the cardiovascular system. For instance, it can promote differentiation of stem cells into
cardiomyocytes and endothelial cells, and boost the function of mesenchymal stem cells and endothelial progenitor cells. These activities of VEGF
are mediated in part through the AKT signaling transduction pathway. In humans, alternative splicing from the single VEGF-A gene gives rise to
multiple VEGF splice variants encoding 121, 145, 165, 189, and 206 amino acids. All isoforms contain a signal peptide sequence, but only the
VEGF121, 145, and 165 species are secreted and readily diffusible presumably due to the absence of a putative heparin-binding domain. The
recombinant human VEGF121 is expressed as a GST-fusion protein. The fusion junction of the protein harbors an engineered thrombin cleavage
site and a protein kinase A (PKA) phosphorylation site. The GST portion of the fusion protein can be cleaved off by thrombin if necessary. The
fusion protein can be radioactively labeled with 32P-r-ATP and PKA.
Biomedical Research Service
& Clinical Application
The figure shows GST-VEGF121-mediated
activation of AKT in cultured C2C12
myoblasts after VEGF treatment.